Release Date: 27/05/20 09:30 Summary: Strong Investor Support for the Exercise of Listed Options Price Sensitive: No Download Document 200.79KB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%